H. Lundbeck, annual report 2002

Revenue rose 24% to DKK 9,488 million.

Cipramil DKK 5,187 million (up 14%), Cipralex DKK 78 million, Celexa DKK 2,378 million (up 44%), Lexapro DKK 777 million, Ebixa DKK 29 million

Profit from operations up 29% to DKK 2,361 million

Net financials represented an expense of DKK 286 million.

Profit before tax up 9% to DKK 2,075 million. Profit after tax down 3% to DKK 1,269 million.

Revenue forecast to rise by about 10% and profit from operations by about 12% in 2003.